trending Market Intelligence /marketintelligence/en/news-insights/trending/8reboBZM6s2vDggP4W2u9g2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Foamix seeks US FDA approval for acne drug

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Blog

COVID-19 Impact & Recovery: Investment Banking


Foamix seeks US FDA approval for acne drug

Foamix Pharmaceuticals Ltd. submitted an application seeking U.S. Food and Drug Administration approval for its acne drug FMX101.

The Israel-based company is seeking the regulator's nod for FMX101 as a therapy for inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients aged 9 years and older.

The application is based on the results of two late-stage trials, called FX2014-05 and FX2017-22.